Collaboration agreed
Evotec AG has announced a multi-year collaboration with Boehringer Ingelheim to jointly identify novel targets in Alzheimer’s disease. The collaboration will also involve the Research Institute of Molecular Pathology in Vienna, which is largely sponsored by Boehringer Ingelheim.
Evotec scientists together with the IMP will apply proprietary disease models to identify the targets. Based on these models, Boehringer Ingelheim will select and further validate target candidates for its in-house drug discovery programme. Financial details of this collaboration are not disclosed.
The contract also includes an option for Evotec to support Boehringer Ingelheim in the target validation process, in which case Evotec will be eligible for milestone payments of up to €20 million plus royalties.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.